Logo image of CYAD.BR

CELYAD ONCOLOGY (CYAD.BR) Stock Analyst Earnings Estimates

EBR:CYAD - Euronext Brussels - BE0974260896 - Common Stock - Currency: EUR

0.458  -0.02 (-4.58%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023
Revenue
YoY % growth
CYAD.BR revenue by date.CYAD.BR revenue by date.

-100.00%		102K
EBITDA
YoY % growth
CYAD.BR ebitda by date.CYAD.BR ebitda by date.
-24.87M
-64.21%		-4.333M
82.58%		-8.75M
-101.94%
EBIT
YoY % growth
CYAD.BR ebit by date.CYAD.BR ebit by date.
-26.39M
-55.45%		-5.773M
78.12%		-9.544M
-65.32%
Operating Margin
CYAD.BR operating margin by date.CYAD.BR operating margin by date.
N/AN/A-9,356.86%
EPS
YoY % growth
CYAD.BR eps by date.CYAD.BR eps by date.
N/A
38.42%		N/AN/A

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
CYAD.BR Yearly EPS VS EstimatesCYAD.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1 -2 -3 -4
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q2 2024
Q2Q % growth		 14K
-68.18%		%
Q2 2021
Q2Q % growth
-100.00%		%
Q4 2020
Q2Q % growth
-100.00%		%
CYAD.BR Yearly Revenue VS EstimatesCYAD.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A